Hear
Takeda is an organization deeply characterized by a Japanese work philosophyin which the ethics and quality of its products and services made available to patients are part of its founding values and have remained unchanged.
In 1781, at age 32, young Chobei Takeda began selling traditional Chinese and Japanese medicinal herbs in Doshomachi, the medicinal district of Osaka, Japan. Chobei bought medicines from wholesalers and, in a small shop, divided them into individual lots to sell to doctors and local medicine merchants.
Through that original activity, he was founding what is today the Takeda laboratory, which 243 years later is consolidated among the first 12 global pharmaceutical companies.
Today the company is present in 80 countries, with around 50 thousand employees. Its global research center is located in Cambridge, Massachusetts, in the United States, and it has production centers in Japan, Germany, Austria, Denmark, Belgium, Brazil, China, Colombia, United States, Estonia, Indonesia, Ireland, Italy, Mexico, Norway, Poland, United Kingdom, Russia and Switzerland.
In Argentina, Takeda has been present since 2011 but took a great leap in visibility when in November 2023 it made its quadrivalent dengue vaccine available to our community, coinciding with the largest dengue outbreak in the history of our country. .
The headquarters of the SAM Region is managed from Argentina, which includes all Latin American countries (except Brazil) and Central America. There is also a quality control laboratory in the town of Olivos, Province of Buenos Aires. The total number of Takeda staff in our country reaches 235 collaborators.
But for Ben Kubik, the General Manager of Austrian nationality who leads the laboratory’s operations in Argentina, Takeda is “much more than the dengue vaccine”.
Ben Kubik, General Manager of Takeda
Each year, Takeda invests $4.8 billion in research and development globally. Currently, they have 25 therapies in an advanced stage of research and with some launches that will take place between this year and 2025. Among them, precision therapies can be highlighted for the treatment of severe oncological conditions, as well as innovations in gastroenterology and neurology. These initiatives are powered by the use of data and advanced digital technology, which accelerates the development and delivery of innovative treatments to improve the lives of patients.
Takeda concentrates its portfolio on six therapeutic areas: Oncology, Gastroenterology, Rare Diseases, Vaccines, Plasma-Derived Therapies and Neurosciences. The focus is on highly innovative medicines that help make a difference in people’s lives. They offer new therapeutic alternatives, improve their collaborative research & development (R&D) engine and their capabilities to generate a robust and diversified product line.
Takeda has achieved carbon neutrality in its plant operations. This was obtained thanks to the internal measures adopted, which include the acquisition of energy that protects the environment, investment in certificates of renewable alternatives and high-quality carbon emission offsets. In addition, it aims to achieve net zero greenhouse gas (GHG) emissions in its production before 2035 and throughout its value chain before 2040.
During the current year, Takeda obtained certification in Argentina as one of the best companies to work for (Top Employer®) for the eighth consecutive year, a distinction that has also been received in 23 other countries.
The certification arises from a survey of 20 topics, among which strategies to attract and retain talent, the work environment, hiring, learning and development are analyzed. It also considers the work environment in terms of well-being, equity, diversity and inclusion. At Takeda they do not make any type of distinction based on gender, age, ethnicity, religion, or political thought.
Takeda is considered a company with a culture based on values, putting the patient first, and then highlighting the role of trust, reputation and finally the business.
Some important principles are integrity, fairness, honesty and perseverance, which represent the pillars that make the company’s foundations solid and remain unchanged.
________________________________________________________
Content LAB is LA NACION’s idea and content generation unit for brands with distribution on their digital platforms and social networks. This content was produced for an advertiser and published by the Content LAB. The editorial staff of LA NACION was not involved in the generation of this content.
THE NATION
